Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin J Shattock

Showing results (191-200 of 211) with videos related to

Pageof 22
Sort By:
The Lancet. Infectious Diseases|August 17, 2019
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trialSonya Abraham, Helene B Juel, Peter Bang, et al.
Cell Reports. Medicine|September 27, 2022
Innate cell markers that predict anti-HIV neutralizing antibody titers in vaccinated macaquesMatthieu Van Tilbeurgh, Pauline Maisonnasse, Jean-Louis Palgen, et al.
Journal of Clinical Microbiology|September 4, 2009
Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysisNicola Richardson-Harman, Carol Lackman-Smith, Patricia S Fletcher, et al.
Retrovirology|October 3, 2014
Aggregate complexes of HIV-1 induced by multimeric antibodiesDaniel J Stieh, Deborah F King, Katja Klein, et al.
NPJ Vaccines|April 22, 2022
Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimersAlessandra Gallinaro, Maria Franca Pirillo, Yoann Aldon, et al.
Ebiomedicine|January 3, 2025
Experimental medicine study with stabilised native-like HIV-1 Env immunogens drives long-term antibody responses, but lacks neutralising breadthKatrina M Pollock, Hannah M Cheeseman, Leon R McFarlane, et al.
Plos One|May 10, 2016
Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre StudyCatherine A Cosgrove, Charles J Lacey, Alethea V Cope, et al.
Frontiers in Immunology|June 10, 2017
A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine RegimensSven Kratochvil, Paul F McKay, Jakub T Kopycinski, et al.
Frontiers in Immunology|March 10, 2017
A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization RegimesSarah Joseph, Killian Quinn, Aldona Greenwood, et al.
Plos Pathogens|October 21, 2025
Induction of HIV-1-specific antibody-mediated effector functions by native-like envelope trimers in humansMarloes Grobben, Emma I M M Reiss, Angela I Schriek, et al.
Pageof 22

Showing results (191-200 of 211) with videos related to

Sort By:
Pageof 22
The Lancet. Infectious Diseases|August 17, 2019
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trialSonya Abraham, Helene B Juel, Peter Bang, et al.
Cell Reports. Medicine|September 27, 2022
Innate cell markers that predict anti-HIV neutralizing antibody titers in vaccinated macaquesMatthieu Van Tilbeurgh, Pauline Maisonnasse, Jean-Louis Palgen, et al.
Journal of Clinical Microbiology|September 4, 2009
Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysisNicola Richardson-Harman, Carol Lackman-Smith, Patricia S Fletcher, et al.
Retrovirology|October 3, 2014
Aggregate complexes of HIV-1 induced by multimeric antibodiesDaniel J Stieh, Deborah F King, Katja Klein, et al.
NPJ Vaccines|April 22, 2022
Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimersAlessandra Gallinaro, Maria Franca Pirillo, Yoann Aldon, et al.
Ebiomedicine|January 3, 2025
Experimental medicine study with stabilised native-like HIV-1 Env immunogens drives long-term antibody responses, but lacks neutralising breadthKatrina M Pollock, Hannah M Cheeseman, Leon R McFarlane, et al.
Plos One|May 10, 2016
Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre StudyCatherine A Cosgrove, Charles J Lacey, Alethea V Cope, et al.
Frontiers in Immunology|June 10, 2017
A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine RegimensSven Kratochvil, Paul F McKay, Jakub T Kopycinski, et al.
Frontiers in Immunology|March 10, 2017
A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization RegimesSarah Joseph, Killian Quinn, Aldona Greenwood, et al.
Plos Pathogens|October 21, 2025
Induction of HIV-1-specific antibody-mediated effector functions by native-like envelope trimers in humansMarloes Grobben, Emma I M M Reiss, Angela I Schriek, et al.
Pageof 22